Literature DB >> 26453564

Protective effects of Xiongshao Capsule () on anti-inflammatory function of high-density lipoprotein in an atherosclerosis rabbit model.

Yan-Hong Zhang1, Ying Zhang2, Jing Li3, Wen-Xin Tong2, Feng-Qin Xu4.   

Abstract

OBJECTIVE: To observe the effects of Xiongshao Capsule (, XSC) on anti-inflflammatory properties of high-density lipoprotein (HDL), myeloperoxidase (MPO) and paraoxonase 1 (PON1) in serum of atherosclerosis (AS) rabbit model and explore the anti-inflflammatory protective effects of XSC on HDL.
METHODS: Sixty rabbits were randomized into the control, the model, XSC low-, medium- and high-dose (Rhizoma Chuanxiong + Radix Paeoniae rubra: 0.6+0.3, 1.2+0.6, 2.4+1.2g·kg-1·day-1, respectively), and simvastatin (1g·kg-1·day-1) groups. The model rabbits were fed with high-fat diet and drugs for 15 weeks. The blood and thoracic aortas samples were collected at the end of 15 weeks. The levels of serum MPO and PON1 as well as total cholesterol (TC) and free cholesterol (FC) in aorta wall cells were tested by enzyme linked immunosorbent assay.
RESULTS: TC and FC in the model group were significantly higher than those in the control group (P<0.01). Compared with the model group, TC and FC in the XSC groups were signifificantly lower (P<0.05 or P<0.01), so was simvastatin group (P<0.01). There was no signifificant difference in PON1 level between groups (P>0.05), even between model and control groups (P>0.05). The serum MPO level in the model group was signifificantly higher than that in the control group (P<0.05), which was signifificantly lower in XSC groups as well as simvastatin group (P<0.05 or P<0.01), and no difference was found between XSC groups and simvastatin group (P>0.05).
CONCLUSIONS: XSC can reduce the serum MPO level in AS rabbits to protect the anti-inflammatory function of HDL, maintaining the normal lipid transport function. TC and FC levels in aorta cells decline, and this process initiated by XSC plays an anti-AS role.

Entities:  

Keywords:  Chinese medicine; anti-atherosclerosis; anti-inflammatory; blood-activating and stasis-dissolving; functional high density lipoprotein

Mesh:

Substances:

Year:  2015        PMID: 26453564     DOI: 10.1007/s11655-015-2298-8

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  18 in total

Review 1.  Assessing the functional properties of high-density lipoproteins: an emerging concept in cardiovascular research.

Authors:  Michela Triolo; Wijtske Annema; Robin P F Dullaart; Uwe J F Tietge
Journal:  Biomark Med       Date:  2013-06       Impact factor: 2.851

2.  Effects of native and myeloperoxidase-modified apolipoprotein a-I on reverse cholesterol transport and atherosclerosis in mice.

Authors:  Bernd Hewing; Saj Parathath; Tessa Barrett; Wing Ki Kellie Chung; Yaritzy M Astudillo; Tadateru Hamada; Bhama Ramkhelawon; Thomas C Tallant; Mohamed Shaif S Yusufishaq; Joseph A Didonato; Ying Huang; Jennifer Buffa; Stela Z Berisha; Jonathan D Smith; Stanley L Hazen; Edward A Fisher
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-01-09       Impact factor: 8.311

Review 3.  High-density lipoprotein function recent advances.

Authors:  Benjamin J Ansell; Karol E Watson; Alan M Fogelman; Mohamad Navab; Gregg C Fonarow
Journal:  J Am Coll Cardiol       Date:  2005-10-19       Impact factor: 24.094

4.  Inflammation modulates human HDL composition and function in vivo.

Authors:  Margarita de la Llera Moya; Fiona C McGillicuddy; Christine C Hinkle; Michael Byrne; Michelle R Joshi; Vihn Nguyen; Jennifer Tabita-Martinez; Megan L Wolfe; Karen Badellino; Leticia Pruscino; Nehal N Mehta; Bela F Asztalos; Muredach P Reilly
Journal:  Atherosclerosis       Date:  2012-02-28       Impact factor: 5.162

Review 5.  Why targeting HDL should work as a therapeutic tool, but has not.

Authors:  Mary G Sorci-Thomas; Michael J Thomas
Journal:  J Cardiovasc Pharmacol       Date:  2013-09       Impact factor: 3.105

6.  Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.

Authors:  Philip Barter
Journal:  Am J Cardiol       Date:  2009-11-16       Impact factor: 2.778

7.  [Effect of xiongshao capsule on lipid metabolism and platelet aggregation in experimental atherosclerosis rabbits].

Authors:  Li-zhi Li; Jian-gang Liu; Lu-bo Ma
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  2008-12

8.  Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase.

Authors:  Baohai Shao; Chongren Tang; Abhishek Sinha; Philip S Mayer; George D Davenport; Nathan Brot; Michael N Oda; Xue-Qiao Zhao; Jay W Heinecke
Journal:  Circ Res       Date:  2014-03-19       Impact factor: 17.367

9.  Plasma HDL reduces nonesterified fatty acid hydroperoxides originating from oxidized LDL: a mechanism for its antioxidant ability.

Authors:  Mari Kotosai; Sachiko Shimada; Mai Kanda; Namiko Matsuda; Keiko Sekido; Yoshibumi Shimizu; Akira Tokumura; Toshiyuki Nakamura; Kaeko Murota; Yoshichika Kawai; Junji Terao
Journal:  Lipids       Date:  2013-03-14       Impact factor: 1.880

10.  Reduced paraoxonase 1 activity as a marker for severe coronary artery disease.

Authors:  Chiyan Zhou; Jia Cao; Liang Shang; Chuanfeng Tong; Hanling Hu; Hui Wang; Daping Fan; Hong Yu
Journal:  Dis Markers       Date:  2013-07-28       Impact factor: 3.434

View more
  4 in total

1.  Effects of Zhizi Chuanxiong Capsule () on the Abnormal Methylation in Rabbits with Atherosclerosis.

Authors:  Qing-Bing Zhou; Li-Qi Wu; Yin Zhang; Zhi-Fang Zhang; Feng-Qin Xu
Journal:  Chin J Integr Med       Date:  2018-05-11       Impact factor: 1.978

2.  Pre-treatment with simvastatin prevents the induction of diet-induced atherosclerosis in a rabbit model.

Authors:  Nikolaos Oikonomidis; Nikolaos Kavantzas; Laskarina-Maria Korou; Panagiotis Konstantopoulos; Vasilios Pergialiotis; Evangelos Misiakos; Ioannis Rizos; Christos Verikokos; Despina N Perrea
Journal:  Biomed Rep       Date:  2016-10-17

Review 3.  Efficacy and Safety of Xue-Fu-Zhu-Yu Decoction for Patients with Coronary Heart Disease: A Systematic Review and Meta-Analysis.

Authors:  Shuo Zhang; Zhen-Lin Chen; Yu-Ping Tang; Jin-Long Duan; Kui-Wu Yao
Journal:  Evid Based Complement Alternat Med       Date:  2021-09-29       Impact factor: 2.629

Review 4.  Adjuvant herbal therapy for targeting susceptibility genes to Kawasaki disease: An overview of epidemiology, pathogenesis, diagnosis and pharmacological treatment of Kawasaki disease.

Authors:  Bin Tang; Hang Hong Lo; Cheng Lei; Ka In U; Wen-Luan Wendy Hsiao; Xiaoling Guo; Jun Bai; Vincent Kam-Wai Wong; Betty Yuen-Kwan Law
Journal:  Phytomedicine       Date:  2020-03-18       Impact factor: 5.340

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.